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Abstract 
Cancer is a deadly and ever present disease in humans and its treatment has become a focus of 
many types of research. This project was designed to synthesize a platinum complex that will 
cross-link DNA and in turn cause cell death for rapidly dividing cells (usually cancer cells). The 
target compound strongly resembled the structure of a nucleic acid, thymidine. Further, nucleic 
acids are extremely important to cell life and cell membranes have transporters specific for them. 
Therefore, the purpose to exploring this new platinum complex was to create compound that a 
cell can easily transport inside its cell and nuclear membranes. With an end product structure in 
mind, a series of seven reactions were attempted in the lab in order to create this compound. 
Upon purification by column chromatography, each intermediate was tested for structure and 
purity using nuclear magnetic resonance spectroscopy (NMR) and thin-layer chromatography 
(TLC). 
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Introduction 
Cancer is defined as the disease caused by an uncontrolled division of abnormal 
cells in an organ or section of the body 7. Unfortunately, cancer is everywhere in our 
world and kills millions of humans a year. Although, within the last fifty years our 
knowledge of cancer and our ability to combat this deadly disease has increased 
significantly. Current drugs or treatments, such as cisplatin and other forms of 
chemotherapy, have allowed certain types and early stage cancer to be considered 
curable diseases. One of the key mechanisms utilized by many of these anti-cancer 
drugs or treatments is the disruption of the cell’s DNA integrity. DNA, or 
deoxyribonucleic acid, is the genetic material needed for proper cell function, growth, 
and replication 1. Accordingly, cells dedicate many resources and mechanisms in 
order to maintain the reliability of their genetic code through costly repair and 
signaling pathways 2.In addition, if the DNA of a cell is altered or destroyed beyond 
repair, most cells will experience G2 arrest of the cell cycle and will follow one of 
two outcomes 2. First, the cell could continuously attempt methods of repair and 
deplete its supply of ATP/NADH; thus inadequate resources lead to cell death 8. This 
cell killing process is called necrosis. In the second outcome, DNA damage causes 
signal transduction; thus causing the cell to implement a programed cell death process 
known as apoptosis. The goal of many anti-cancer drugs is to permanently alter the 
DNA of a cancer cell and cause cell death via necrosis or apoptosis.  
The cisplatin drug mentioned above is a key pharmaceutical anti-cancer drug that 
modifies DNA structure by cross-linking DNA. As used here, cross-linking is defined 
as a link between two nucleotide bases. For cisplatin, the cross-link is accomplished 
by the use of a platinum complex. In order to understand the mechanism behind the 
anti-cancer drug family of platinum complexes, cisplatin’s mechanism of action will 
be examined in detail. As seen by the structure in Figure 1, cisplatin is a small 
inorganic molecule with the chemical formula of Pt(Cl)2(NH3)2. 
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The cornerstone to the medicinal usefulness of cisplatin and other platinum 
complexes is the presence of the electrophilic platinum II ion. Specifically, it is this 
positive platinum II ion that is attracted to the electron rich atoms of DNA molecules, 
making cross-linking possible 3. In the case of cisplatin, the drug has affinity for, or 
prefers, the cross-linking of guanine bases 8. Specifically, cisplatin binds to the 
nucleophilic N7 of two guanine residues (Fig. 2a). It should be noted that the 
geometry of the platinum complex is most effective in the cis, not trans, stereoisomer 
(Fig. 2b).This is because the trans stereoisomer causes inter-strand binding which is 
more easily repaired than the inter-strand binding caused by the cis stereoisomer 1. 
Once the platinum is covalently bonded to the nitrogen atoms, the steric strain of 
the base residues being brought into closer proximity creates a “kink” in the DNA. 
This change in DNA structure disrupts the DNA base stacking; therefore decreasing 
the stability and even causing unwinding of the DNA helix 5. The three dimensional 
“kink” created by cisplatin can be seen in Fig. 3 below 1.  
Figure 1: Structure of 
cisplatin 
Figure 2: 2a) Cisplatin forming a cross-link with the N7 nitrogens of two guanine residues. 2b) The 
intra-strand versus inter-strand DNA cross-links of cisplatin 
P a g e  | 3 
 
With the mechanism of cisplatin understood, other platinum II complexes can be 
introduced. Many other anti-cancer drugs, as seen in Fig. 4, are platinum complexes 
that use the same DNA cross-linking mechanism as cisplatin 4.  
 
In the presence of these types of cross-links, critical DNA replication enzymes are 
slowed or unable to commence, sustain, and terminate DNA replication. In treatment 
with low doses of cisplatin, human cells have been found to use the general DNA 
Figure 3: 3D representation of cisplatin cross-linking DNA and disrupting 
DNA base stacking via creating a "kink" 
Figure 4: Examples of platinum II complex drugs 
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damage recovery pathways of mismatch repair and an increase in replicative bypass 2. 
With sufficient dosage, human cells are unable to repair the DNA damage caused by 
cross-linking and succumb to necrosis or apoptosis.  
By definition, cancer cells are nearly always replicating; thus are more susceptible 
to the DNA cross-linking abilities of cisplatin and other platinum complexes. In fact, 
when cisplatin was first introduced in clinical use, the cure rate of many solid 
malignancies was increased significantly. Most notable was the cure rate of testicular 
cancer which was increased from 10% to 85% 8. It should be noted that despite the 
ability of cisplatin and other platinum complexes to combat some types of cancer, 
their effectiveness in other types of cancers is more limited because of acquired or 
intrinsic resistance 6. 
Further rendering the effectiveness of this drug class is the fact that the entirety of 
molecular mechanisms that underlie human cell’s resistance to platinum complexes 
are poorly understood 4.Specifically, there is a transport problem. Platinum 
complexes are positively charged inorganic compounds; making successful 
transportation to the DNA of the cell difficult. The platinum II ion is prone to form 
bonds and interactions with the nucleophilic atoms of many molecules and proteins of 
the human body. Therefore, in order to induce DNA cross-linking with these 
complexes, they are administered to patients intravenously in high dosages. The 
necessity for high dosages of platinum complexes are known to cause side effects that 
include: kidney damage, nerve damage, nausea and vomiting, and hear lose 8. 
Consequently the ongoing second generation of platinum complex drugs aims to be 
more effective at lower dosages.  
Although several routes could be taken to try to improve upon these drugs need 
for high concentration, solving the transportation issue is a sought after result. If the 
drug were some molecule that could easily be up taken by the cell, less concentration 
would be needed in the form of a direct injection to a tumor.  
In line with this realization, the goal of this research project was to synthesize and 
purify a platinum complex that is incorporated on a nucleoside. It is key to note the 
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incorporation of the nucleoside. Cells have a multitude of protein transporters 
designated for nucleosides and nucleotides, as they are the molecular building blocks 
of DNA, a necessity to cell life. With the inclusion of a nucleoside, the target 
compound was designed as a pro-drug that would allow transportation of a reactive 
platinum complex into the cell. As the end goal product of a series of seven reactions, 
this target compound was a thymidine nucleoside with a platinum II complex 
coordinated to a picolinic acid residue that is attached to the nucleoside. This 
attachment is designed to bind platinum-chloride. The intended reactions, 
intermediates, and end product can be seen in Fig. 5 on page 6. This project’s goal 
was to synthesize this end project and prove its structure from proton and platinum 
NMR. 
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Scheme 1: Proposed Reaction Series of Target compound 
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Experimental Methods and Data 
Reaction 1 – Synthesis of Compound 1 
Reaction 1 was performed in two separate steps. The starting material was picolinic acid 
(7.015g, 5.686E-2 mol) and was dissolved into thionyl chloride (SOCl2) (24.0mL, 3.304E-1 
mol) in a 100mL round bottom flask. The flask was placed in a heating mantle and fit with a 
water condenser and breathing apparatus. Once dissolved, a catalytic amount (3-4 drops) of 
dimethylformamide (DMF) was added to the flask. The solution was stirred and heated by the 
mantle. It was brought to reflux (roughly 75oC) which was maintained for 20 hours.  The 
result of this step was the creation of an acid chloride from the carboxylic acid attachment, 
creation of an ionic salt via the protonated nitrogen and chlorine ion, and electrophilic 
aromatic addition of chlorine. Scheme 1 below outlines Step 1 of Reaction 1.  
The following day, a standard distillation apparatus was setup in order to remove the 
excess thionyl chloride from the resulting solution. Immediately after Step1 was stopped at 
the end of its allowed time, the flask containing the product of Step 1 was used as the 
distillation flask and distillation began. As distillation proceeded, the collecting flask was 
slowly filled with thionyl chloride that was being removed from our distillation flask. After 
the distillation system stopped dripping, signaling the absence of thionyl chloride from our 
product, the product was kept heated to prevent precipitate formation. While kept warm by a 
jacketed addition funnel, the product solution was slowly dripped over the course of 20 
minutes into a 100mL round bottom flask that contained a stirring solution of 6mL of 
methanol (CH3OH) and 6mL of toluene. Once completely added, the stirring solution was 
placed into an ice bath for 1 hour in order to allow for precipitation of Compound 2. Vacuum 
filtration was then used to separate and dry the product. In addition to vacuum filtration, the 
solid product was placed in a clean, dry, and massed 25mL round bottom flask that was 
placed on a vacuum pump overnight in order to further dry the solid. Step 2 of this reaction 
created a methyl ester out of the acid chloride group, an esterification reaction. Scheme 1, as 
seen below, outlines both steps of Reaction 1.  
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Scheme 2: Reaction 1 – Step 1: Synthesis protonation of aromatic nitrogen to create a salt and addition of 
chlorine via electrophilic aromatic addition. Step 2: Esterification of the acid chloride group.  
In the highest yield of Reaction 1, 3.7199g of Compound 1 (208.044 g/mol) was isolated. 
This is a percent yield of 31.45%. A proton and carbon NMR were taken and were found 
consistent with assigned structure.  1H NMR (DMSO, 300MHz): 10.10-9.25 (exchangeable 
H, 11H, NH); 8.74 (d,5H,CH); 8.22 (s,5H,CH); 7.85 (d,2H, CH); 3.90 (s,8H,CH3); 2.48 (s, H, 
DMSO). Figure 6 shows the 1H NMR of Compound 1. 13C NMR (DMSO, 300MHz):164.17 
(CH,7C); 151.21 (CH, 2C); 149.03 (C, 6C); 144.19 (C, 4C); 127.41 (CH,  3C); 124.92 (CH, 
5C); 52.819 (CH3, 8C).
 
Figure 5: Proton NMR of Compound 1 
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Reaction 2 – Synthesis of Compound 2 
Reaction 2 was taken in order to neutralize the salt, which was done with a strong basic 
solution of NaOH. Compound 1 (3.6011g, 1.731E-2 mol) was dissolved and stirred in a 
solution of 25mL of water and NaOH (.7222g, 1.805E-2 mol). A color change occurred (light 
clear yellow to opaque dark yellow) as the solution was stirred in a 100mL round bottom 
flask at room temperature for 1 hour. Next, the product of the solution was extracted with 
diethyl ether in a separatory funnel. In the four washes that took place, the top organic layer 
(diethyl ether) was kept. The product was then removed from the diethyl ether via rotary 
evaporation into a clean pre-weighed 50mL round bottom flask. After beign massed, our 
highest yield of Compound 2 (172.034g/mol) was 1.7239g. The theoretical yield of Reaction 
2 was 2.9780g; therefore the highest percent yield was 57.89%. A 1H NMR was taken to 
check the structure of this compound, which was found consistent with the assigned structure. 
The process of Reaction 2 is outlined in Scheme 2.  
 
Scheme 3: Reaction 2 - Neutralization of the salt by removable of proton via addition of a strong base 
Reaction 3 – Synthesis of Compound 3 
The purpose of Reaction 3 was to substitute the aromatic chlorine with a thiourea group. 
Reaction 3 began in the same flask containing the dried Compound 2 (1.7239g, 1.002E-2 
mol). 14.00mL of methanol was stirred into the flask, dissolving the Compound 2. Once 
dissolved, thiourea (1.6009g, 76.12, 2.103E-2 mol) was added and stirred into the solution. 
Next, the solution was brought to reflux (roughly 70oC) for 2 hours. The resulting solution 
then had the solvent removed by rotary evaporation into a clean pre-massed 50mL round 
bottom flask. The resulting syrup of Compound 3 (.05855g, 211.240g/mol) was massed and a 
1H NMR was taken. The theoretical yield of Reaction3 was 2.1168g; therefore the highest 
percent yield was 27.66%. The outline of Reaction 3 is seen in Scheme 3. 
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Scheme 4: Reaction 3 - Subsitution of chlorine with thiourea 
Reaction 4 – Synthesis of Compound 4 
The purpose of Reaction 4 was to oxidize the thiourea group into a thiol. The syrup of 
Compound 3 from multiple successful trials of Reaction 3 (.344g, 1.628E-3 mol) was kept in 
a 50mL round bottom flask. In a separate flask, sodium bicarbonate (NaHCO3, .6010g, 
7.153E-3 mol) was dissolved in 9.00mL of water. Once dissolved, the sodium bicarbonate 
solution was added to the flask containing Compound 3. While stirring, sodium 
hypophosphite (NaPO2H2, .2006g, 2.280E-3 mol) was then added to the flask. A slight color 
change from yellow to orange was noted with this addition. The solution was stirred at room 
temperature in the hood with a breathing apparatus for one hour. After the hour, solvent was 
removed via rotary evaporation.  The outline of Reaction 4 can be seen in Scheme 4. 
 
Scheme 5: Reaction 4 - Oxidation of the thiourea group into thiol 
Thin layer chromatography (TLC), using a 10% methanol and 90% chloroform solution, 
was then used in order to test the purity of the syrup product. Under ultraviolet light, the TLC 
test showed three separate bands, or three molecules with varying polarities. In order to 
purify the three bands, column chromatography was used. A solution of 7% methanol and 
93% chloroform allowed for sufficient separation in the bands. Each of the three bands were 
collected and solvent was removed via rotary evaporation into separate pre-weighted 25mL 
round bottom flasks. Accordingly, a 1H NMR was taken of each of the three solid products. 
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The NMR spectra revealed the three compounds seen in the figure below. Two of the solids 
were our starting materials (Compound 2 and Compound 3) and the other was Compound 4 
(169.20 g/mol, .0101g, 5.969E-5 mol). The three compounds are seen and labeled in Figure 7. 
The theoretical yield for reaction 3 was .2755g of Reaction 4, meaning our highest percent 
yield was 3.44%.  
 
Figure 7: The three molecules purified from column chromatography after Reaction 4  
It should be noted that when Reaction 4 was attempted again, Compound 4 was not 
synthesized. 1H NMR revealed that the band previously corresponding to Compound 4 was 
now a disulfide. The disulfide was a product of oxidation of two of the thiol groups of 
Compound being in the presence of oxygen. While being stored in the freezer, Compound 4 
had oxidized into its disulfide. Reaction 4 was repeated except under the presence of nitrogen 
gas, but the disulfide was created again. The 1H NMR of the disulfide is seen in Figure 8.    
Figure 8: Proton NMR of the disulfide of Compound 4 
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1H NMR (DMSO, 300MHz): 8.76 (d, 5H, CH); 8.74 (d,5H,CH); 8.21 (s,2H,CH); 7.75 (d,4H, 
CH); 4.09 (s,8H,CH3); 2.48 (s, H, DMSO).  
Reaction 5 – Synthesis of Compound 5 
The purpose of reaction 4 was to attach the nucleoside, thymidine, by synthesizing a 
thioester. Even though compound 3 could not be isolated, reaction 4 was attempted with the 
disulfide of compound 3 as the starting material. The 25mL flask containing the disulfide of 
compound 3 (.0101g, 5.969E-5 mol) was dissolved in tetramethylguanadine (.05055mL, 
4.029E-3 mol). Once dissolved, anhydrothymidine (.0956g, 3.980E-4 mol) was stirred into 
the solution. With the use of an oil bath, condenser, and breathing apparatus, the solution was 
heated to 100oC for 20 hours. After the 20 hour period, the resulting solution was dried via 
rotary evaporation. TCL testing in 10% methanol and 90% chloroform showed the presence 
of one molecule. A 1H NMR was taken for the solid and this spectrum revealed the disulfide 
as the only present compound.  The outline of the intended reaction 4 is seen below in Figure 
12. No reaction had taken place and our research was stopped here.  
 
Scheme 6: Reaction 5 – Synthesis of a thioester by attaching thymidine 
 
If we had continued, the following reactions would have been carried out. Refer back to 
Scheme 1 for the follow reactions. 
Reaction 6 – Synthesis of Compound 6 
Compound 5 was to be treated with potassium hydroxide, ethanol, and water in the same 
step. This reaction would have serve as a saponification of the ester attachment made in 
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Reaction 2; thus recreating the carboxylic acid attachment. The outline of the proposed 
Reaction 6 is seen below in Scheme 7. 
 
Scheme 7: Reaction 6 - Recreation of carboxlylic attachment via saponification of the ester attachment 
Reaction 7 – Synthesis of Compound 7 
Compound 6 will be taken through a two-step reaction designed to bind platinum. First, 
sodium hydroxide will be used to deprotonate the carboxylic acid attachment of Compound 6. 
In the second step, cis PtCl2(DMSO)2, will be added into the solution. One of the two 
chlorines attached to the platinum would have acted as a leaving group, thus allowing the 
platinum to bind to both the nitrogen of our attachment ring and the deprotonated oxygen of 
the carboxylic acid. The outline of the proposed Reaction 6 is seen below in Scheme8. 
 
Scheme 8: Reaction 7 - Deprotonating of the carboxylic acid attachment and binding of the platinum ion 
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Conclusions 
The target nucleoside platinum II complex was not successfully synthesized. Even 
though Reaction 3 was complete, the thiol Compound 3 was oxidized in the presence 
of oxygen gas; thus creating an unreactive disulfide. Attempts of Reaction 3 under 
nitrogen gas and Reaction 4 using the disulfide at the reactant both proved ineffective. 
Although this target molecule could not be synthesized, other nucleoside platinum 
complexes could be new target molecules. Specifically, a nucleoside platinum 
complex that does not involve a thiol intermediate could be sought after. Two 
examples of new target molecules being explored in Dr. Church’s lab include a 
thymidine and adenosine platinum complex. These structures are shown below in 
Figure 9.   
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Figure 9: Possible new target nucleoside platinum II complexes for further research 
Thymidine Platinum 
II Complex 
Adenosine Platinum II 
Complex 
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